Abstract 16083: How Will the Use of New Heart Failure Treatments Impact US Health System Reimbursement Under Alternative Payment Models: Measuring the Impact of Sotagliflozin Use Among Patients Hospitalized for Heart Failure

Abstract

Background: In the SOLOIST-WHF clinical trial, sotagliflozin lowered rates of readmission and emergency department (ED) visits among patients hospitalized for worsening heart failure (HF), but its impact on health systems’ finances is unclear. Research Question: What is the economic impact of the adoption of sotagliflozin on health systems after incorporating reimbursement bonuses within alternative payment models (APM)? Goal: To quantify the financial impact on health systems of adopting sotagliflozin relative to standard of care (SoC) for treating patients with HF as in SOLOIST-WHF. Methods: This study created a decision tree model and estimated the clinical impact of sotagliflozin use relative to SoC from the SOLOIST-WHF trial. The model first assessed the impact of sotagliflozin on re-hospitalization, ED visit rates and mortality. Next, these clinical outcomes were translated into impacts on a health system’s finances relative to SoC within a one-year time frame under traditional fee-for-services (FFS) and three APMs: hospital readmissions reduction program (HRRP), Bundled Payments for Care Improvement (BPCI), and Accountable Care Organization (ACO). Results: An average community hospital (6,109 admissions annually) would have 83 patients per year with an index HF hospitalization. Sotagliflozin reduced the probability of re-hospitalization, ED visits, and deaths by 29.3%, 38.5%, and 17.8%, respectively vs. SoC. For hospitals not experiencing capacity constraint, sotagliflozin adoption increased financial returns by $9,365 per person (pp) ($781,340 per health system) under HRRP, $1,200 pp. ($100,106 per health system) for BPCI, and $1,078 pp. ($89,910 per health system) for ACO. (Figure 1) Conclusion: Sotagliflozin adoption decreased hospitalizations, ED visits, and deaths, which—under various APMs—led to a net positive financial impact on health systems after accounting for APM bonus payments. Sponsorship: Lexicon Pharmaceuticals, Inc.